- Conatus Pharmaceuticals (CNAT -3.4%) initiated with Buy rating and $15 (165% upside) price target by H.C. Wainwright.
- Vascular Biogenics (VBLT -5.5%) initiated with Buy rating and $25 (141% upside) price target by Chardan Capital.
- Adamas Pharmaceuticals (ADMS -5.4%) initiated with Buy rating and $29 (63% upside) price target by Aegis Capital.
- Aquinox Pharmaceuticals (AQXP -4.2%) initiated with Outperform rating and $26 (48% upside) price target by Leerink.
- Intrexon (XON -6.1%) initiated with Buy rating and $69 (66% upside) price target by Stifel.
- Galectin Therapeutics (GALT -2.6%) initiated with Buy rating and $7 (210% upside) price target by H.C. Wainwright.
- Infinity Pharmaceuticals (INFI -6.7%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target lowered to $13 (51% upside) from $15.
- Immunogen (IMGN -5.3%) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $9 (15% downside risk) from $10.
- Horizon Pharma (HZNP -3.3%) downgraded to Hold from Buy by Brean Capital. Price target removed.